Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Illinois LAI Antipsychotic Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IllinoisPolicy N/A

    Long-Acting Injectable (LAI) Atypical Antipsychotics

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Illinois policy alerts

    Know when Blue Cross Blue Shield - Illinois releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and utilization of preferred and non-preferred LAI atypical antipsychotics for adults with schizophrenia, schizoaffective disorder, or bipolar I disorder when consistent with the specific medication's FDA labeling. It applies to providers requesting coverage through Blue Cross Blue Shield of Illinois.

    Policy Summary
    PayerBlue Cross Blue Shield - Illinois
    PolicyLong-Acting Injectable (LAI) Atypical Antipsychotics
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2021
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing that all initial criteria are met; preferred agents may be approved for 3 months.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum patient age for initial coverage
    3 monthsApproval period for initial requests
    3Covered diagnostic categories listed in the criteria
    10LAI atypical antipsychotic products addressed in the dosing guide

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Board-certified psychiatristRequired prescriber specialty

    Coverage Criteria

    Preferred LAI Atypical Antipsychotic — Initial Therapy

    Covered for initial therapy when ALL of the following criteria are met:

    ALL of the following

    • Patient is ≥ 18 years old.
    • Diagnosis is schizophrenia, schizoaffective disorder, or bipolar 1 in accordance with the medication's specific FDA labeling.
    • Prescriber is a board-certified psychiatrist.
    • Documented history or stabilization

      • History of nonadherence to oral antipsychotics.
      • Stabilization on a long-acting injectable (LAI) atypical antipsychotic while in a mental health facility.
    • Patient has documented oral tolerability of the active ingredient in accordance with the medication's specific FDA labeling.

      A request for Invega Trinza also requires a documented trial of Invega Sustenna for at least 4 months.

    • The treatment regimen is within the medication's specific FDA labeling, and there are no contraindications or significant drug interactions to treatment.
    • There is evidence of an outpatient follow-up appointment; if unavailable, the prescriber agrees to coordinate the follow-up appointment and administration of the next LAI atypical antipsychotic dose in accordance with the medication's specific FDA labeling.

    Non-preferred LAI Atypical Antipsychotic Therapy

    For a non-preferred LAI atypical antipsychotic, the preferred-therapy criteria must be met, including the following additional criterion:

    ALL of the following

    • There is documented clinically significant treatment failure, intolerance, or contraindication to preferred LAI atypical antipsychotic agents.

    Medical Exceptions

    Requests for medically necessary exceptions to these criteria are reviewed on a case-by-case basis.

    ALL of the following

    • The prescriber submits sufficient clinical documentation supporting the medical necessity of an exception to the applicable coverage criteria.
    • The exception is determined to be medically necessary through case-by-case review.

    The prescribed treatment regimen must not be outside the medication's specific FDA labeling. Coverage is subject to the absence of contraindications and significant drug interactions, as specified in accordance with the medication's specific FDA labeling. Initial requests are approved for 3 months.

    Provider Actions and Documentation

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for an initial request for a long-acting injectable (LAI) atypical antipsychotic. An initial approval is limited to 3 months.

    • Approval applies only when all applicable initial-request criteria are met.
    Prior Authorization

    Medical Exception Review

    Requests for a medically necessary exception to the coverage criteria are reviewed on a case-by-case basis.

    • Submit clinical rationale and supporting documentation for the requested exception.
    Step Therapy

    Preferred-Agent Step Requirement

    Policy Background

    LAI atypical antipsychotics are intended to support appropriate treatment utilization for patients with repeated nonadherence to oral antipsychotic therapy. Patients with schizophrenia are at increased risk of relapse without treatment, and those with recurrent relapses associated with partial or complete oral-treatment nonadherence may be candidates for LAI therapy.

    Definitions and Abbreviations

    DEFINITIONS
    AAPAtypical antipsychotics
    DEFINITIONS
    ERExtended-release
    DEFINITIONS
    IMIntramuscular
    DEFINITIONS
    POBy mouth/oral administration

    Initial Therapy Criteria

    General Initial Authorization

    All initial LAI atypical antipsychotic requests must satisfy the following criteria.

    Initial LAI authorization: Patient is at least 18 years old; has a diagnosis supported by the requested product's FDA labeling; is treated by a board-certified psychiatrist; has documented nonadherence to oral antipsychotics or stabilization on an LAI atypical antipsychotic in a mental health facility; has documented oral tolerability of the active ingredient; has an FDA-label-consistent regimen without contraindications or significant drug interactions; and has a follow-up and next-dose administration plan.Initial approval 3 months

    Non-preferred products additionally require clinically significant treatment failure, intolerance, or contraindication to preferred LAI atypical antipsychotic agents.

    Product-Specific Initiation Prerequisites

    The following product-specific initiation prerequisites apply when the requested product is indicated.

    Invega Trinza initiation:

    Continuation Criteria

    Long-Acting Paliperidone Transitions

    Longer-interval paliperidone products require adequate prior treatment with earlier paliperidone formulations.

    Invega Trinza transition: Start Invega Trinza only after at least 4 months of adequate treatment with Invega Sustenna; the last 2 Invega Sustenna doses should be the same strength.>=4 months of Invega Sustenna

    Invega Trinza is administered every 3 months.

    Invega Hafyera transition: Start Invega Hafyera only after a trial of Invega Sustenna for at least 4 months and a trial of Invega Trinza for at least one 3-month cycle.>=4 months of Invega Sustenna and >=1 3-month Invega Trinza cycle

    Invega Hafyera is administered every 6 months in the gluteal muscle.

    Step Therapy Requirements

    StepMedication or requestRequirement
    1Non-preferred LAI atypical antipsychoticDocument clinically significant treatment failure, intolerance, or contraindication to preferred LAI atypical antipsychotic agents.
    StepMedicationRequired prior treatment
    2Invega TrinzaDocument at least 4 months of adequate treatment with Invega Sustenna; the last 2 Sustenna doses should be the same strength.
    2Invega HafyeraDocument at least 4 months of treatment with Invega Sustenna and at least one 3-month cycle of Invega Trinza.

    Administration Site and Route

    Billing Rule

    Follow product-specific administration-site guidance

    Administer each product using the route, anatomical site, and dosing guidance specified in its product labeling. Depending on the product, administration may be intramuscular in the deltoid or gluteal muscle or subcutaneous in the abdomen; Invega Hafyera must be administered in the gluteal muscle.

    • Confirm the product-specific administration route and anatomical site before office administration.
    • Invega Hafyera is administered only in the gluteal muscle.
    • Perseris is administered by subcutaneous injection into the abdomen.
    Policy Summary
    PayerBlue Cross Blue Shield - Illinois
    PolicyLong-Acting Injectable (LAI) Atypical Antipsychotics
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2021
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing that all initial criteria are met; preferred agents may be approved for 3 months.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and DocumentationPolicy BackgroundDefinitions and AbbreviationsInitial Therapy CriteriaContinuation CriteriaStep Therapy RequirementsAdministration Site and Route

    A non-preferred LAI atypical antipsychotic requires documented clinically significant treatment failure, intolerance, or contraindication to preferred LAI atypical antipsychotic agents.

    • The exception must be clinically supported in the medical record.

    Unsupported block type: documentation

    Unsupported block type: step_therapy

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    DEFINITIONS
    FDAUnited States Food and Drug Administration
    Document a trial of Invega Sustenna for at least 4 months before initiating Invega Trinza. The last 2 Invega Sustenna doses should be the same strength.
    >=4 months of Invega Sustenna

    Adequate treatment with Invega Sustenna must precede Invega Trinza.

    Invega Hafyera initiation: Document a trial of Invega Sustenna for at least 4 months and a trial of Invega Trinza for at least one 3-month cycle before initiating Invega Hafyera.>=4 months of Invega Sustenna plus >=1 3-month Invega Trinza cycle